Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;9(4):1447-1451.
doi: 10.1002/iid3.495. Epub 2021 Jul 22.

The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom

Gema Requena  1 , John Logie  2 , Daniel C Gibbons  2 , Jonathan Steinfeld  3 , Melissa K Van Dyke  4
Affiliations

The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom

Gema Requena et al. Immun Inflamm Dis. 2021 Dec.

Abstract

Introduction: Data on the burden of hypereosinophilic syndrome (HES) are limited. This study investigated the incidence and prevalence of HES using real-world data from patients in the United Kingdom.

Methods: Primary care data from the Clinical Practice Research Datalink were analyzed. The patients of interest were identified using medical codes specific for HES. Annual incidence rates and prevalence were estimated for the years 2010-2018 (inclusive) using patients observed for a minimum period of one year.

Results: Between 2010 and 2018, 93 patients were identified with HES. During the study period the incidence of HES ranged from less than 0.04, 95% confidence interval (CI) (0.01-0.07) to 0.17, 95% CI (0.10-0.26) per 100,000 person-years and the prevalence ranged from 0.15, 95% CI (0.10-0.25) to 0.89, 95% CI (0.74-1.09) cases per 100,000 persons. Sensitivity analyses varying the minimum observation period required to identify HES patients gave similar results.

Conclusion: These results provide estimates of the burden of HES in the United Kingdom and indicate that whilst HES is a very rare disease, there is evidence that is increasingly being recorded in UK primary care.

Keywords: United Kingdom; hypereosinophilic syndrome; incidence; prevalence.

PubMed Disclaimer

Conflict of interest statement

Gema Requena, John Logie, Daniel C. Gibbons, Jonathan Steinfeld, and Melissa K. Van Dyke are employees of GSK and own stocks/shares in GSK. Editorial support was provided by Kerry Knight, PhD, at Fishawack Indicia Ltd., UK, and was funded by GSK.

Figures

Figure 1
Figure 1
Annual incidence of hypereosinophilic syndrome in the UK Clinical Practice Research Datalink from 2010 to 2018. CI, confidence interval. *In accordance with the standard Clinical Practice Research Datalink policy, no cell counts with less than 5 (or rates based on them) should be shared
Figure 2
Figure 2
Annual prevalence of hypereosinophilic syndrome in the UK Clinical Practice Research Datalink from 2010 to 2018. CI, confidence interval
See this image and copyright information in PMC

References

    1. Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am. 2007;27(3):357‐375. - PMC - PubMed
    1. Curtis C, Ogbogu P. Hypereosinophilic syndrome. Clin Rev Allergy Immunol. 2016;50(2):240‐251. - PubMed
    1. Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607‐612e609. - PMC - PubMed
    1. Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48:1740. 10.1093/ije/dyz034 - DOI - PMC - PubMed
    1. Gotlib J. World Health Organization‐defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(11):1243‐1259. - PubMed

Publication types